22 Jan Utilization of Potentially Inappropriate Medications in Patients with Major Neurocognitive Disorders
Posted at 14:22h
in
Utilization of Potentially Inappropriate Medications in Patients with Major Neurocognitive Disorders
HC0099
Overview
Background
- Major neurocognitive disorders (MNCD), previously known as dementia, includes a broad range of conditions, with Alzheimer disease being the most common subtype. Its prevalence is low in people younger than 65 but increases sharply with age. Data suggests a growing prevalence in Canada due to the ageing population.
- Acetylcholinesterase inhibitors and memantine are used to manage symptoms and improve quality of life. Other drugs like antipsychotics, antidepressants, and anxiolytics are often used to manage the behavioural and psychological symptoms of dementia, though these carry important risks, including increased mortality and risks of cognitive impairment.
- Important gaps remain in our understanding of the epidemiology of MNCD among older adults in Canada, as well as the use of potentially inappropriate medications (PIMs) in this population.
Objectives
- We will replicate the drug utilization study conducted by INESSS using data from Quebec to gather data from additional provinces. The results from the Quebec study will be included into the overall findings.
- The objectives are to identify incident and prevalent cases of MNCD among older adults in each province between the fiscal years 2013–2014 and 2022–2023 and describe their characteristics and a set of indicators on the use of PIMs.